Verteglide 脊柱植入物

Search documents
OrthoPediatrics (KIDS) Q2 Revenue Up 16%
The Motley Fool· 2025-08-06 03:25
Core Insights - OrthoPediatrics reported Q2 2025 GAAP revenue of $61.1 million, slightly below Wall Street's estimate of $61.47 million, while adjusted loss per share narrowed to ($0.11), beating expectations by $0.18 [1][2][10] - The company continues to experience year-over-year growth across core segments, although higher operating expenses have resulted in a net loss position [1][8] Financial Performance - Q2 2025 metrics include a 15.7% year-over-year revenue increase from $52.8 million in Q2 2024, and a gross profit of $44.0 million, up 7.8% from the previous year [2][5] - Adjusted EBITDA improved to $4.1 million, a 57.7% increase year-over-year, while operating expenses grew 17.6% to $54.7 million, leading to an operating loss of $10.6 million [2][10] - The company reported a net loss of $7.1 million in Q2 2025, compared to $6.0 million a year earlier [8][10] Business Overview - OrthoPediatrics specializes in pediatric orthopedic devices, focusing on trauma, deformity correction, scoliosis solutions, and sports medicine devices, addressing a market gap for children [3][4] - The company emphasizes innovation through rapid product development and strategic acquisitions, aiming to enhance its portfolio and market penetration [4] Product Performance - Trauma and deformity correction products generated $41.7 million in Q2 2025, while scoliosis sales reached $18.5 million, growing 34% year-over-year [7] - Specialty bracing under the OPSB division expanded over 20% year-over-year, while sports medicine revenue decreased by 25% [7] International and Domestic Revenue - U.S. revenue contributed $48.1 million, while international revenue was $13.0 million, up from $11.6 million a year earlier, despite slower sales in Latin America [5][6] Outlook and Guidance - Management raised full-year 2025 revenue guidance to $236 to $242 million, implying 16% to 18% growth, and reaffirmed a gross margin range of 72% to 73% [12][13] - The company aims for positive free cash flow in Q4 2025 and breakeven by 2026, with a focus on cash discipline and sustainable profitability [13][14]